William Blair Reaffirms Market Perform Rating for Catalent (NYSE:CTLT)

William Blair reaffirmed their market perform rating on shares of Catalent (NYSE:CTLT) in a research report report published on Tuesday, Benzinga reports.

A number of other brokerages also recently issued reports on CTLT. Barclays boosted their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a research report on Friday, June 28th. Royal Bank of Canada reissued a sector perform rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Finally, StockNews.com initiated coverage on shares of Catalent in a research report on Monday, September 2nd. They set a sell rating for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $58.08.

Catalent Trading Down 0.6 %

NYSE:CTLT opened at $60.03 on Tuesday. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. Catalent has a 12 month low of $31.80 and a 12 month high of $61.20. The company has a market cap of $10.86 billion, a PE ratio of -9.84, a price-to-earnings-growth ratio of 2.52 and a beta of 1.16. The company has a 50 day simple moving average of $58.88 and a two-hundred day simple moving average of $57.07.

Insider Buying and Selling

In related news, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares in the company, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,409 shares of company stock valued at $782,923. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Several hedge funds have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new stake in Catalent in the 2nd quarter worth $208,000. Truist Financial Corp lifted its stake in Catalent by 37.2% in the 2nd quarter. Truist Financial Corp now owns 28,029 shares of the company’s stock worth $1,576,000 after purchasing an additional 7,600 shares in the last quarter. Millennium Management LLC lifted its stake in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. MBB Public Markets I LLC purchased a new stake in Catalent in the 2nd quarter worth $788,000. Finally, APG Asset Management N.V. lifted its stake in Catalent by 26.8% in the 2nd quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock worth $8,157,000 after purchasing an additional 32,900 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.